ABH Angel Biotech

TIDMABH

RNS Number : 9401K

Angel Biotechnology Holdings Plc

29 August 2012

29 August 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel and arGentis Pharmaceuticals LLC sign Framework Agreement

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce the signing of a framework agreement with arGentis Pharmaceuticals LLC ("arGentis") which establishes the parameters of future contracts for the development and manufacture of their collagen product, ARG201, a treatment for the life-threatening autoimmune disease, systemic sclerosis.

Dr Stewart White, ABH Commercial Director and Acting CEO said: "We are very pleased to be able to assist arGentis by providing material for this serious clinical indication. This demonstrates not only the commercial demand for the collagen products that Angel can offer, but the value Angel can offer customers towards accelerating clinical supply."

Mr Tom Davis, President of arGentis Pharmaceuticals, LLC said: "Angel offers a unique combination of product and service that has been a real challenge for our business to identify. We look forward to a long and fruitful relationship with Angel and an expeditious entry of our product to the clinic."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specializes in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has three facilities, employing 38 people: Pentlands Science Park near Edinburgh, a site in Cramlington, near Newcastle-upon-Tyne and Angel Biomedical Ltd facility in Glasgow.

More information is available at www.angelbio.com .

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBKFDKOBKDAFB

Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From Apr 2024 to May 2024

Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From May 2023 to May 2024